Trials / Unknown
UnknownNCT04569825
Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- University Of Anbar · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Background: Anosmia is a debilitating common symptom of COVID-19. The therapeutic effect of systemic steroid for the treatment of anosmia has been studied with various findings of its efficacy. However, the effect of local steroid was not assessed before. Objective: To estimate the efficacy of local steroid in the treatment of anosmia in COVID-19 patients.
Detailed description
Background: Anosmia is a debilitating common symptom of COVID-19. The therapeutic effect of systemic steroid for the treatment of anosmia has been studied with various findings of its efficacy. However, the effect of local steroid was not assessed before. Objective: To estimate the efficacy of local steroid in the treatment of anosmia in COVID-19 patients. Materials and Methods: A double-blinded randomized controlled trial was conducted at Al-Ramadi Teaching Hospital and Tikrit Teaching Hospital during the period from 23th August to 30th September. Proven cases by real-time polymerase chain reaction and presented with anosmia alone or with ageusia were enrolled in the study. The patients divided into 4 groups according to the treatment modalities. Group A (local steroid nasal drops), group B (local normal saline nasal drops), group C (systemic and local steroid), and group D (systemic steroid and local normal saline). Comparison between the groups concerning the fate and the recovery time of the anosmia was analyzed. Results and Conclusion: Depends on the finding of the studied patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ophtamesone | local application intranasally as drops |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2020-09-30
- Completion
- 2020-10-15
- First posted
- 2020-09-30
- Last updated
- 2020-09-30
Locations
1 site across 1 country: Iraq
Source: ClinicalTrials.gov record NCT04569825. Inclusion in this directory is not an endorsement.